Multiple Analysts Lift Guardant Health, Inc. (GH) Targets on Screening and Data Growth

We recently compiled a list of the 7 Most Promising Gene Editing Stocks According to Analysts. Guardant Health, Inc. is one of the most promising stocks.

TheFly reported on December  17 that Mizuho analyst Anthony Petrone maintained an Outperform rating on GH and raised the price target to $120 from $100, reflecting growing confidence in the company’s positioning in cancer diagnostics and growth prospects.

This followed a strong series of price target increases on December 15, including JPMorgan raising its target to $120 from $90 (Overweight), Barclays to $120 from $85 (Overweight), Wells Fargo to $120 from $93 (Overweight), and Leerink Partners to $155 from $115 (Outperform), all underscoring broad analyst optimism.

The bullish sentiment is supported by recent operational progress. On December 11, Guardant Health, Inc. (NASDAQ:GH) announced a strategic collaboration with Trial Library to leverage its genomic testing data and AI‑powered platform to enhance patient identification and access to oncology clinical trials, particularly in underserved communities, strengthening its Biopharma & Data segment alongside its screening business.

GH’s Shield blood‑based colorectal cancer (CRC) screening test continues to demonstrate strong real‑world adoption, with studies showing high patient adherence rates in clinical practice, reinforcing its market potential as an FDA‑approved primary CRC screening option.

Guardant Health, Inc. (NASDAQ:GH) is a leading precision oncology company focused on helping conquer cancer globally through the use of its proprietary blood tests, vast data sets, and advanced analytics.

While we acknowledge the potential of GH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy NOW 

Disclosure: None.